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Abstract
Background and purpose Noninvasive PET imaging of
tumour hypoxia could help in the selection of those patients
who could benefit from chemotherapy or radiation with
specific antihypoxic treatments such as bioreductive drugs
or hypoxic radiosensitizers. In this phase I trial, we aimed
to determine the toxicity of [18F]HX4, a member of the 2-
nitroimidazole family, at different dose levels. The second-
ary aim was to analyse image quality related to the HX4
dose and the timing of imaging.
Methods Patients with a histologically proven solid cancer
without curative treatment options were eligible for this study.
A study design with two dose steps was used in which a single
dose of a maximum of 222 MBq (step 1) or 444 MBq (step 2)
[18F]HX4 was injected. Toxicity was scored on day 0 and on
days 3 and 7 after injection, according to the CTCAE 3.0
scoring system. PET/CT images of the largest tumour site
were acquired 30, 60 and 120 min after injection.
Results Six patients with stage IV carcinoma were included,
four with non-small-cell lung carcinoma, one with thymus
carcinoma, and one with colon carcinoma. No toxicity was
observed in any of the patients at either dose level. The
median tumour to muscle ratio 120 min after injection was
1.40 (range 0.63–1.98).
Conclusion The findings of this study showed that [18F]
HX4 PET imaging for the detection of hypoxia is not
associated with any toxicity. Imaging was successful;
however, future trials are needed to determine the optimal
image parameters.
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Introduction
Tumour hypoxia is an important marker of cancer progno-
sis, being associated with aggressive growth, metastasis,
and resistance to anticancer therapy [1]. Noninvasive PET
imaging with hypoxia-specific 2-nitroimidazoles has the
ability to quantify tumour hypoxia and could help in the
selection of those patients who could benefit from
chemotherapy or radiation with specific antihypoxic treat-
ments such as bioreductive drugs or hypoxic radiosensi-
tizers [2]. Furthermore, in contrast to invasive electrode
measurements, PET imaging provides the opportunity to
display the spatial distribution of hypoxia, which is
essential for its integration with radiation dose distribu-
tion. [18F]Fluoromisonidazole ([18F]FMISO) is the first
radiolabelled 2-nitroimidazole derivative proposed for
hypoxia imaging with PET [3, 4]. The relatively low
uptake of [18F]FMISO observed in hypoxic lesions
coupled with its slow clearance from normoxic tissue,
however, limits the clinical potential of this agent [5]. A
number of other 18F-labelled nitroimidazole derivatives
have been identified, investigated and reported to overcome
these problems [6, 7].
The 2-nitroimidazole nucleoside analogue, 3-[18F]fluoro-
2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-
yl)propan-1-ol ([18F]HX4), was developed as a potential
marker and radiosensitizer for hypoxic tumour cells.
Because of better water solubility and faster clearance, we
expect that [18F]HX4 has better pharmacokinetic properties
than currently used nitroimidazole hypoxia markers such as
[18F]FMISO.
In this phase I trial, we aimed to determine the toxicity
of [18F]HX4 at different dose levels, with the secondary
aim of analysing image quality in relation to the HX4 dose
and timing of imaging.
Methods
Patient inclusion
Patients with a histologically or cytologically confirmed
stage IV solid cancer at any site, primary or secondary,
without curative treatment options, were eligible. Patients
were required to have a WHO performance status of 0 to 1,
normal white blood cell count and differential, normal
platelet count and no anaemia requiring blood transfusion
or erythropoietin. Additional eligibility criteria were ade-
quate hepatic function, adequate renal function (calculated
creatinine clearance at least 60 ml/min), no administration
of 18F in the previous 24 h, and a minimum age of 18 years.
Patients with a recent (<3 months) myocardial infarction,
uncontrolled infectious disease, pregnancy, or concurrent
treatment with anticancer agents or radiotherapy were
excluded.
Approval for the study protocol (NCT00690053) was
obtained from the medical ethics committee and the
radiation safety committee. All patients gave written
informed consent.
Study design
A study design with two dose steps was used (Fig. 1). In
step 1, a single dose of up to 222 MBq [18F]HX4 was
injected, and in step 2 a single dose of up to 444 MBq was
injected. Six patients were included, three in each dose step.
If in any patient a toxicity of grade 2 or more was observed,
three more patients were included in this dose step. If
another toxicity of grade 2 or more occurred in one or more
of three patients, the study would be stopped. If no more
than one of six patients experienced grade 2 toxicity, the
step was considered safe.
Synthesis of [18F]HX4
[18F]HX4 was synthesized from the HX4 precursor in a
two-step process (Fig. 2). The product obtained was
purified and formulated into a sterile and pyrogen-free
solution suitable for use in humans. The radiochemical
purity was required to be higher than 95% in every batch.
The specific radioactivity of [18F]HX4 exceeded 14.8 MBq/
μmol. The radiopharmaceutical was produced at the
government-licensed GMP-compliant (EMEA Eudralex 4)
radiopharmaceutical production facility of the Department
of Nuclear Medicine and PET Research of the VU
University Medical Centre (license number 108897F).
Fig. 1 Flow chart of the study. Asterisks If toxicity of grade 2 or more
was observed in none of these patients, the step was considered safe; if
toxicity of grade 2 or more was observed in one or more patients, the
study was stopped
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PET/CT imaging
PET/CT images of the largest tumour site were acquired 30,
60 and 120 min after injection. Imaging at later time-points
after injection was deliberately avoided to minimize the
burden of the study in these patients with advanced disease.
Images were acquired with the patient in the supine
position. CT and PET images were automatically registered
based on mutual information and were subsequently fused
using dedicated software (TrueD, version VC50; Siemens
Medical, Erlangen, Germany).
The tumour was delineated on the CT scan by the same
observer (J.v.L.). The location of the [18F]HX4 uptake and
the SUVmax (maximal standardized uptake value) were
determined within the delineated tumour using a gradient-
based method which was implemented in the software.
Tumour to muscle ratios (TMR) for [18F]HX4 uptake
were calculated at all time-points by dividing the tumour
SUVmax by the skeletal muscle SUVmax. The skeletal muscle
SUVmax was determined by calculating the average SUVmax
in two circular regions of interest drawn in the paraspinal
muscles.
In patients in whom an [18F]FDG-PET scan was
performed for diagnostic purposes during the week before
or after the [18F]HX4 scan, uptakes of [18F]FDG and [18F]
HX4 were compared. The location of the [18F]FDG uptake
was determined using automated SUV-thresholding with
the threshold depending on the tumour-to-background
signal ratio method [8].
Toxicity scoring
Toxicity was scored on day 0 and on days 3 and 7 after
injection, according to the CTCAE (Common Terminology
Criteria for Adverse Events) version 3.0 scoring system.
Blood was sampled before injection and at each control
point, and the tests included haematology and kidney and
liver function. Due to the relatively short physical half-life
of 18F (110 min) and biological half-life of HX4 (less than
3 h), after 1 day the radioactivity of both the drug and its
metabolites have disappeared and no additional toxicity
from the radiation is expected.
The time-line for each patient entering the study is
illustrated in Fig. 3.
Results
Patient characteristics
Six patients, with a median age of 63 years (range 54–
68 years), were included. The patient characteristics are
shown in Table 1. All patients had a stage IV carcinoma:
four had a non-small-cell lung carcinoma, one had a thymus
carcinoma and one patient a colon carcinoma. Three
patients had stage IV disease at primary diagnosis, while
the others had developed metastases after therapy with
curative intent. All patients had previously undergone
anticancer therapy. Two patients were unable to undergo
Fig. 2 Synthesis of [18F]HX4. The precursor was supplied by
Siemens Molecular Imaging (Erlangen, Germany). The first step is a
nucleophilic substitution of radioactive fluorine (in the form of 18F)
onto the precursor material, yielding the fluorinated intermediate
which is then hydrolysed to obtain the active drug product
Fig. 3 Time-line of the study
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the last scan at 120 min after injection due to pain (not
drug-related).
Toxicity
Results of the toxicity scoring are shown in Table 2. No
toxicity according to the CTCAE 3.0 criteria was observed at
any time-point in the first three patients included in dose step
1. Hence, it was considered safe to continue with dose step 2.
Again, no toxicity was observed in any of the three patients.
One patient reported mild transient headache (grade 1) the
day after the [18F]HX4 injection, which was considered
unlikely to be related to the injection.
Image analysis
Images in two patients at 120 min after injection are
presented in Fig. 4. They show a heterogeneous uptake of
[18F]HX4 throughout the tumour. The median TMR at 30,
60 and 120 min after injection was 1.17 (range 0.20–1.83),
1.25 (range 0.25–1.67) and 1.40 (range 0.63–1.98). In two
of four patients in whom images were available at 120 min
after injection a considerable increase was seen in the TMR
compared to 60 min after injection.
In three patients a [18F]FDG-PET scan performed during
the week before or after the [18F]HX4-PET scan was
available. In these three patients, there was a good
correlation between the uptakes of [18F]FDG and [18F]
HX4 as shown in Fig. 5.
Discussion
Preclinical experience gained with [18F]HX4 and unlabelled
HX4 did not indicate any adverse events at the dose levels
used in these exploratory trials. The current phase I trial
confirmed these preclinical data, with no toxicity according
to the CTCAE 3.0 criteria observed in any of the patients.
The time curves of the TMR showed a large divergence
between the patients. In two patients, a substantial increase in
TMR was seen in the second hour after injection, indicating
that the optimal TMR for imaging may be at later time
Table 1 Patient characteristics
Patient Age
(years)
Sex Height
(m)
Weight
(kg)
WHO performance
status
Primary tumour Prior therapy
Site Histology
1 67 F 1.58 58 1 Lung Adenocarcinoma Chemotherapy, radiotherapy
brain
2 54 F 1.76 64 0 Lung Adenocarcinoma Chemotherapy
3 58 M 1.79 82 0 Thymus Carcinoid Surgery, radiotherapy
4 62 M 1.90 80 1 Lung Adenocarcinoma Surgery, chemotherapy,
radiotherapy
5 63 F 1.70 70 1 Lung Squamous cell
carcinoma
Surgery, chemotherapy
6 68 M 1.68 80 0 Colon Adenocarcinoma Surgery, chemotherapy
Table 2 Toxicity scoring. Toxicity was scored before study entry (baseline) and on days 0, 3 and 7 of the study. The blood test results were
compared with those at baseline and evaluated by the physician
Patient Injected activity (MBq) Vital signsa Toxicity scoringb Medicationa
Haematology Liver function Kidney function Symptoms
1 222 0 0 0 0 0 0
2 222 0 0 0 0 0 0
3 222 0 0 0 0 0 0
4 444 0 0 0 0 1c 0
5 444 0 0 0 0 0 0
6 444 0 0 0 0 0 0
a Every change in vital signs or medication compared to the baseline values was scored “0” indicating no change.
b Grade according to CTCAE version 3.0.
c Mild headache, not related to the 18 F[HX4] administration.
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points. In the three patients in whom an [18F]FDG-PET scan
was available, a good correlation was found between the
hypoxic areas imaged with HX4 and the areas of high FDG
uptake. This is consistent with the often observed relation-
ship between tumour hypoxia and FDG uptake [9, 10].
From the imaging perspective, there were some limi-
tations inherent in the study design. Firstly, the imaging
was limited to 120 min after injection. This time horizon
was chosen to limit the burden on the patients, who were all
suffering from end-stage disease. Future studies, with the
final aim of adapting treatment according to hypoxia, will
be performed in patients with earlier stage disease, in whom
imaging at later time points would be acceptable. Secondly,
only static PET imaging was performed. Hence, no
correction could be made for heterogeneity in tumour
perfusion. With kinetic imaging, tumour perfusion can be
measured, thereby offering the opportunity to differentiate
between differences in delivery of [18F]HX4 and differ-
ences in pO2 within the same tumour [4]. Finally, in order
to allow radiotherapy dose distribution within the tumour
on the basis of hypoxia, the stability of hypoxic regions
within the tumour before and at different time-points during
chemo- and radiotherapy should be assessed.
Conclusion
The results presented show that [18F]HX4 PET imaging
was not associated with any toxicity. Future trials are
Fig. 4 [18F]HX4 images in two
patients. a, b Patient 4 (TMR
1.35): a coronal image, b
transverse image. c, d Patient 5
(TMR 1.98): c coronal image, d
transverse image
Eur J Nucl Med Mol Imaging (2010) 37:1663–1668 1667
needed to determine optimal imaging conditions, with the
final aim of developing adaptive treatment strategies based
on [18F]HX4-imaged hypoxia.
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Fig. 5 Correlation between the
uptakes of [18F]HX4 and [18F]
FDG (patient 5). FDG uptake in
the tumour was delineated using
automated SUV thresholding
depending on the tumour-to-
background signal ratio. The
HX4-positive regions in the tu-
mour were delineated using
gradient-based image analysis.
a, b 18FDG-PET/CT images: a
axial, b coronal. c, d [18F]HX4-
PET/CT images: c axial,
d coronal
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